Valeo Pharma Dirección

Dirección controles de criterios 1/4

We currently do not have sufficient information about the CEO.

Información clave

Al Moghaddam

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	1.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Al Moghaddam (57 yo)

less than a year

Permanencia

Mr. Al Moghaddam, B. Com. CMA had been a Director at Valeo Pharma Inc. since March 21, 2024 until June 2024 and served as its Chief Development Officer since June 2024 until August 2024 and serves as its C...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kyle Steiger	Senior VP & Chief Commercial Officer	2.3yrs	CA$388.21k	0.020% € 576.9
Al Moghaddam	Chief Executive Officer	less than a year	sin datos	sin datos
Pascal Tougas	Chief Financial Officer	less than a year	sin datos	sin datos
Frederic Dumais	Director of Communications & Investor Relations	3.8yrs	sin datos	sin datos
Guy-Paul Allard	VP of Legal Affairs & Corporate Secretary	no data	sin datos	0.41% € 11.9k
Jean Fournier	Head of Ophthalmology Business Unit	2.3yrs	sin datos	sin datos

2.3yrs

Permanencia media

Equipo directivo experimentado: VP2's management team is considered experienced (2.3 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Raich	Independent Director	less than a year	sin datos	0.18% € 5.2k
Richard MacKay	Chairman of the Advisory Board & Director	15.8yrs	sin datos	16.44% € 482.7k
Steven Saviuk	Chairman	21.7yrs	CA$466.29k	0.18% € 5.4k
Marc Leger	Independent Non-Executive Director	2.6yrs	sin datos	2.36% € 69.4k
Richard Lajoie	Independent Director	less than a year	sin datos	sin datos
Charles Bisaillon	Independent Director	less than a year	sin datos	sin datos

1.8yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: VP2's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Valeo Pharma Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Valeo Pharma Inc. Announces Board Changes

Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of Directors

Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors

Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024

Valeo Pharma Inc. Announces Board Changes

Valeo Pharma Inc. Announces Chief Financial Officer Changes

Recent updates

Third quarter 2024 earnings released: CA$0.083 loss per share (vs CA$0.069 loss in 3Q 2023)

Valeo Pharma Inc. to Report Q3, 2024 Results on Sep 12, 2024

Valeo Pharma Inc. Announces Board Changes

Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of Directors

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: CA$0.079 loss per share (vs CA$0.077 loss in 2Q 2023)

Second quarter 2024 earnings released: CA$0.079 loss per share (vs CA$0.077 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Valeo Pharma Inc. to Report Q2, 2024 Results on Jun 13, 2024

New major risk - Market cap size

Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors

First quarter 2024 earnings released: CA$0.08 loss per share (vs CA$0.077 loss in 1Q 2023)

Valeo Pharma Inc. to Report Q1, 2024 Results on Mar 14, 2024

Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024

Valeo Pharma Inc. Announces Board Changes

No longer forecast to breakeven

Full year 2023 earnings released: CA$0.32 loss per share (vs CA$0.32 loss in FY 2022)

Valeo Pharma Inc. to Report Q4, 2023 Results on Jan 29, 2024

Valeo Pharma Inc. Announces Chief Financial Officer Changes

Valeo Pharma Inc. Announces Appointment of Mr. Richard Lajoie to Board of Directors

New major risk - Market cap size

New minor risk - Profitability

Third quarter 2023 earnings released: CA$0.069 loss per share (vs CA$0.058 loss in 3Q 2022)

Valeo Pharma Inc. to Report Q3, 2023 Results on Sep 13, 2023

Valeo Pharma Inc. announced that it has received CAD 4.499999 million in funding from Investissement Québec

Less than half of directors are independent

Valeo Pharma Inc. Announces Board Appointments

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: CA$0.077 loss per share (vs CA$0.063 loss in 2Q 2022)

Valeo Pharma Inc. to Report Q2, 2023 Results on Jun 13, 2023

First quarter 2023 earnings released: CA$0.077 loss per share (vs CA$0.074 loss in 1Q 2022)

Valeo Pharma Obtains Public Reimbursement for Onstryv in Quebec

Full year 2022 earnings released: CA$0.32 loss per share (vs CA$0.20 loss in FY 2021)

Valeo Pharma Announces Filing of New Drug Submission-Covid 19 with Health Canada for Sabizabulin for the Treatment of Hospitalized Covid-19 Patients

Valeo Pharma Inc. to Report Q4, 2022 Results on Jan 30, 2023

Valeo Pharma Inc. Announces Stepping Down of Frederic Fasano as President and Chief Operating Officer

Less than half of directors are independent

Valeo Pharma Inc. Revises Revenue Guidance for the Fourth Quarter of 2022

Valeo Pharma Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: CA$0.058 loss per share (vs CA$0.042 loss in 3Q 2021)

Valeo Pharma Inc. to Report Q3, 2022 Results on Sep 13, 2022

Valeo Pharma Announces Executive Appointments

Key Executive recently bought €83k worth of stock

Second quarter 2022 earnings released: CA$0.063 loss per share (vs CA$0.028 loss in 2Q 2021)

Valeo Pharma Inc. to Report Q2, 2022 Results on Jun 14, 2022

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Valeo Pharma Inc., Annual General Meeting, Apr 27, 2022

Valeo Pharma Inc. to Report Q4, 2021 Results on Feb 28, 2022

Valeo Pharma's Hespercotm Now Available At Loblaws, Hesperidin Covid-19 Clinical Trial Results Submitted for Publication

Valeo Pharma Inc. announced that it expects to receive CAD 20 million in funding from Investissement Québec, Investment Arm and other investors

Key Executive recently bought €63k worth of stock

Key Executive recently bought €53k worth of stock

Third quarter 2021 earnings released: CA$0.042 loss per share (vs CA$0.028 loss in 3Q 2020)

Senior VP & CFO recently bought €67k worth of stock

Valeo Pharma Announces Additional Provincial Reimbursement Coverage for Redesca™ and Redesca HP™

Senior VP & CFO recently bought €136k worth of stock

Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.015 loss in 2Q 2020)

Valeo Pharma Inc. has completed a Composite Units Offering in the amount of CAD 10 million.

Valeo Pharma Inc. Announces Commercial Launch of Enerzair Breezhaler and Atectura Breezhaler

Valeo Pharma Inc. Announces Outlook for Its Second Quarter Ended April 30, 2021

Valeo Pharma Inc. announced that it has received CAD 6.645 million in funding

President recently bought €117k worth of stock

Valeo Pharma Inc. announced that it expects to receive CAD 4 million in funding

First quarter 2021 earnings released: CA$0.027 loss per share (vs CA$0.02 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.082 loss per share (vs CA$0.073 loss in FY 2019)

Valeo Pharma Inc., Annual General Meeting, Apr 28, 2021

New 90-day low: €0.67

Valeo Pharma Inc. to Report Q4, 2020 Results on Feb 24, 2021